- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05804448
Effekt av høyde på postdural punkteringshodepine etter keisersnitt
Effekt av høyde på postdural punkteringshodepine etter keisersnitt: en prospektiv, multisenter kohortstudie
The aim of this study is to examine the effects of altitude (high altitude versus low altitude) on incidence and severity of postural puncture headache (PDPH) following spinal anaesthesia for caesarean delivery. The investigators hypothesized that the risk of PDPH would be higher in highlander parturients than in lowlander parturients.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This will be a prospective cohort study conducted in two different altitudes in Nepal. The high-altitude site is in Jumla, approximately 2514 m above the sea level, and a low altitude city is Dharan, located at 350 m from sea level.
The investigators will screen the eligible participant admitted to the in-patient obstetric unit. The investigator will also record patient baseline characteristics, preoperative anxiety, antenatal depression, presence of chronic pain conditions or preexisting headache. Spinal anaesthesia will be administered in the sitting position at the L3-L4 or L4-L5 interspace using a 25-G pencil point spinal needle (Pencan® 25-gauge).
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Asish Subedi, MD
- Telefonnummer: 9842040604
- E-post: ashish.subedi@bpkihs.edu
Studiesteder
-
-
Karnali
-
Jumla, Karnali, Nepal, 2069
- Rekruttering
- Karnali Academy of Health Sciences
-
Ta kontakt med:
- Robin Khapung, MD
- Telefonnummer: 9849481562
- E-post: robinkhapung@hotmaail.com
-
-
Koshi
-
Dharān, Koshi, Nepal, 56700
- Rekruttering
- BP Koirala Institute of Health Sciences (BPKIHS)
-
Ta kontakt med:
- Asish Subedi, MD
- Telefonnummer: 2013 977-25-525555
- E-post: ashish.subedi@bpkihs.edu
-
Hovedetterforsker:
- Asish Subedi, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Parturients planned for elective and non-elective (category 2 & 3) caesarean section under spinal anaesthesia.
Beskrivelse
Inclusion Criteria:
- Parturient, aged more than or equal to 18 years
- American society of Anesthesiologist 2 and 3
- Scheduled for elective and non-elective (category 2 & 3) caesarean delivery with spinal anesthesia
- Native to their resident altitude i.e., those born, raised, and have continuously lived at the same altitude, at least for the past 1 year.
Exclusion Criteria:
- Hypertensive disorder
- Cerebrovascular disease
- Mental disorder (schizophrenia and other psychotic disorders)
- Known fetal anomalies
- Contraindication to spinal anaesthesia.
- Those requiring general anaesthesia for delivery due to failed spinal anesthesia
- Major post-delivery complications (severe haemorrhage, sepsis, or ICU admission)
- Those who migrate from their resident altitude (either low to high or vice versa) within 7 days post-delivery will also be excluded.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
High-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude above 2500 m from sea level will receive spinal anesthesia for caesarean section. |
|
Low-altitude group
Parturient who are native to their resident altitude, i.e. residing at the altitude below 500 m from sea level will receive spinal anesthesia for caesarean section. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
The diagnosis of post-dural puncture headache will be based on the international headache society ICDH-3 criteria: a headache that occurs within 5 days of a dural puncture, is located in the occipital and/or frontal areas, worsens within 15 min of sitting or standing and alleviates within 15 min after lying down, associated with at least one of the following features: neck stiffness, nausea, vomiting, photophobia, and tinnitus, and resolves either spontaneously within 1 week or within 48 h after effective treatment. |
up to 7 days after spinal anesthesia
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with severity of postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
using a numeric rating scale (NRS), with 0= NO pain 10=worst imaginable pain, and classified as none (NRS=0), mild (1-3), moderate (4-6), and severe (7-10) |
up to 7 days after spinal anesthesia
|
|
Number of patients with non-postdural puncture headache
Tidsramme: up to 7 days after spinal anesthesia
|
Headache that is not related to posture |
up to 7 days after spinal anesthesia
|
|
Number of patients who received treatment for postdural puncture headache
Tidsramme: up to 1 month after occurrence of PDPH
|
paracetamol, NSAID's, caffeine, opioids, glossopharyngeal nerve block, sphenopalatine ganglion block and epidural blood patch |
up to 1 month after occurrence of PDPH
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 533/2022 P
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .